Your browser doesn't support javascript.
loading
Non-cleavable hinge enhances avidity and expansion of CAR-T cells for acute myeloid leukemia.
Leick, Mark B; Silva, Harrison; Scarfò, Irene; Larson, Rebecca; Choi, Bryan D; Bouffard, Amanda A; Gallagher, Kathleen; Schmidts, Andrea; Bailey, Stefanie R; Kann, Michael C; Jan, Max; Wehrli, Marc; Grauwet, Korneel; Horick, Nora; Frigault, Matthew J; Maus, Marcela V.
Affiliation
  • Leick MB; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Silva H; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA.
  • Scarfò I; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Larson R; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Choi BD; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA; Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Bouffard AA; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA.
  • Gallagher K; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Schmidts A; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Bailey SR; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA.
  • Kann MC; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA.
  • Jan M; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA; Department of Pathology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Wehrli M; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA.
  • Grauwet K; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA.
  • Horick N; Department of Biostatistics, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.
  • Frigault MJ; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA 02114, USA.
  • Maus MV; Cellular Immunotherapy Program, Cancer Center, Massachusetts General Hospital, Boston, MA 02129, USA; Harvard Medical School, Boston, MA 02115, USA; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA 02114, USA. Electronic address: mvmaus@mgh.harvard.edu.
Cancer Cell ; 40(5): 494-508.e5, 2022 05 09.
Article in En | MEDLINE | ID: mdl-35452603

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Receptors, Chimeric Antigen Limits: Humans Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Leukemia, Myeloid, Acute / Receptors, Chimeric Antigen Limits: Humans Language: En Journal: Cancer Cell Journal subject: NEOPLASIAS Year: 2022 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos